(S,R,S)-AHPC-C1-NH2

Background Introduction

(S,R,S)-AHPC-C1-NH2 is a high-purity E3 ligase ligand-linker conjugate designed for use in targeted protein degradation research, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It incorporates the potent Von Hippel-Lindau (VHL) ligand (AHPC) with a flexible linker ending in a primary amine (NH2), enabling seamless conjugation with various target-binding moieties. This makes (S,R,S)-AHPC-C1-NH2 a critical building block in modern chemical biology and drug discovery workflows.

Mechanism

(S,R,S)-AHPC-C1-NH2 operates by leveraging the ubiquitin-proteasome pathway through the formation of bifunctional molecules, commonly known as PROTACs. The AHPC component selectively binds to the VHL E3 ubiquitin ligase complex, while the terminal amine enables coupling with ligands that target proteins of interest. Upon formation of the complete PROTAC, the targeted protein is brought into proximity with the E3 ligase, facilitating ubiquitination and subsequent proteasomal degradation of the target protein. This specific mechanism allows for the selective elimination of disease-related proteins within cells.

Applications

(S,R,S)-AHPC-C1-NH2 is widely used in the synthesis of PROTAC molecules for target validation, chemical probe development, and next-generation drug discovery. Its applications span oncology, neurodegenerative disease, immunology, and other therapeutic areas where protein degradation provides a novel therapeutic strategy. Researchers use this conjugate to design and optimize PROTACs that address previously undruggable protein targets, aiding in both basic research and preclinical drug development.

• High-affinity VHL ligand ensures potent E3 ligase recruitment for targeted protein degradation.
• Amino-terminated linker enables efficient and flexible PROTAC assembly, facilitating customizable drug design.